Predictive biomarkers of benefit to axitinib plus avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC)

被引：0
|
作者：
Hoff, Camilla Oliveira
McGrail, Daniel
Heeke, Simon
de Sousa, Luana Guimaraes
Li, Kaiyi
Bell, Diana
Mitani, Yoshitsugu
Marques-Piubelli, Mario L.
Cortez, Maria Angelica
Lin, Shiaw-Yih
Elamin, Yasir Y.
El-Naggar, Adel K.
Ferrarotto, Renata
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Cleveland Clin, Cleveland, OH USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6096
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study)
    Iacovelli, Roberto
    Atzori, Francesco
    Basso, Umberto
    Bersanelli, Melissa
    Bonomi, Lucia
    Bracarda, Sergio
    Buttigliero, Consuelo
    Fantinel, Emanuela
    Calabro, Fabio
    Chiuri, Vincenzo Emanuele
    Di Lorenzo, Giuseppe
    Fornarini, Giuseppe
    Massari, Francesco
    Naglieri, Emanuele
    Ortega, Cinzia
    Procopio, Giuseppe
    Milella, Michele
    Santoni, Matteo
    Vitale, Maria Giuseppa
    Zucali, Paolo Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [32] Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study
    Iacovelli, Roberto
    Ciccarese, Chiara
    Buti, Sebastiano
    Zucali, Paolo Andrea
    Fantinel, Emanuela
    Bimbatti, Davide
    Verzoni, Elena
    Accettura, Caterina
    Bonomi, Lucia
    Buttigliero, Consuelo
    Fornarini, Giuseppe
    Pipitone, Stefania
    Atzori, Francesco
    Masini, Cristina
    Massari, Francesco
    Primi, Francesca
    Strusi, Alessandro
    Giudice, Giulia Claire
    Perrino, Matteo
    Maruzzo, Marco
    Milella, Michele
    Giannarelli, Diana
    Brunelli, Matteo
    Procopio, Giuseppe
    Tortora, Giampaolo
    EUROPEAN UROLOGY, 2024, 86 (05) : 411 - 419
  • [33] Phase II trial evaluating axitinib for patients with uaresectable, recurrent, or metastatic (R/M) bead and neck squamous cell carcinoma (HNSCC)
    Sacco, Assuntina Gesualda
    Zhao, Lill
    Carey, Thomas E.
    Dobrosotskaya, Irina Y.
    McHugh, Jonathan B.
    Chepeha, Douglas Brian
    Bradford, Carol Roasler
    Wolf, Gregory T.
    Prince, Mark E.
    Moyer, Jeffrey
    McKean, Erin Lynn
    McLean, Scott A.
    Malloy, Kelly M.
    Spector, Matthew E.
    Hogikyan, Norman D.
    Urba, Susan
    Ward, Brent
    Worden, Francis P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).
    Kang, Hyunseok
    Ahn, Myung-Ju
    Keam, Bhumsuk
    Bowles, Daniel W.
    Wong, Deborah J. L.
    Ho, Alan Loh
    Kim, Sung-Bae
    Worden, Francis P.
    Jang, Tak Yun Seong
    Meng, Xianzhang
    Hanna, Glenn J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut).
    Ferrarotto, Renata
    Metcalf, Robert
    Rodriguez, Cristina P.
    Muzaffar, Jameel
    Even, Caroline
    Perez, Augusto
    Herpen, Carla M. L. -Van
    Oliva, Marc
    Xia, Bing
    Bowles, Daniel W.
    Popovtzer, Aharon
    Winquist, Eric
    Wirth, Lori J.
    Hao, Desiree
    Kang, Hyunseok
    Hotte, Sebastien J.
    Stemmer, Salomon M.
    Mehra, Ranee
    Worden, Francis P.
    Ho, Alan Loh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] Phase II study on lenvatinib (LEN) in recurrent and/or metastatic (R/M) adenoid cystic carcinomas (ACC) of the salivary glands (SG) of the upper aereodigestive tract (NCT02860936)
    Locati, Laura
    Galbiati, Donata
    Calareso, Giuseppina
    Alfieri, Salvatore
    Granata, Roberta
    Bossi, Paolo
    Bergamini, Cristiana
    Resteghini, Carlo
    Cavalieri, Stefano
    Platini, Francesca
    Quattrone, Pasquale
    Mancinelli, Moela
    Zucchella, Andrea
    Mariani, Luigi
    Fedele, Guido
    Licitra, Lisa F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma.
    Schoenfeld, Jonathan Daniel
    Mahmood, Umair
    Chen, Yu-Hui
    Mak, Raymond H.
    Lorch, Jochen H.
    Hanna, Glenn J.
    Sridharan, Vishwajith
    Bang, Andrew
    Busse, Paul Martin
    Willers, Henning
    Mamon, Harvey J.
    Yoo, Hyung-Jin
    Pai, Sara I.
    Wirth, Lori J.
    Haddad, Robert I.
    Chau, Nicole Grace
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] WHAT IS THE CURRENT UPDATE ON ADVANCED METASTATIC ADENOID CYSTIC CARCINOMA ( ACC) PATIENTS RECEIVING SYSTEMIC THERAPY IN THE NEW ERA OF MOLECULAR PROFILING?
    Oishi, Karen
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [39] Phase II trial of apatinib in patients with recurrent and/or metastatic adenoid cystic carcinoma of the head and neck: Updated analysis.
    Zhu, Guopei
    Zhang, Lin
    Li, Rongrong
    Dou, Shengjin
    Yang, Wenjun
    Zhang, Chenping
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] ACCURACY a phase (P) II trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): Preliminary safety and efficacy data
    Ferrarotto, R.
    Ho, A.
    Wirth, L. J.
    Muzaffar, J.
    Rodriguez, C.
    Dekel, E.
    Walker, R. M.
    Nadri-Shay, C.
    Vergara-Silva, A.
    ANNALS OF ONCOLOGY, 2019, 30
12345